Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
Bioptimizers offers health and nutrition supplements.
Bioptimizers offers health and nutrition supple...
Aravive is developing treatments designed to halt progression of life-threatening ...
Aravive is developing treatments designed to ha...
Akcea Therapeutics is a development and commercialization company focused on helpi...
Akcea Therapeutics is a development and commerc...
Akero aims to develop and deliver transformational medicines to patients with high...
Akero aims to develop and deliver transformatio...
We are a late stage biopharmaceutical company focused on the development and comme...
We are a late stage biopharmaceutical company f...
NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisens...
NeuBase Therapeutics, Inc. is developing its mo...
ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company d...
ASLAN Pharmaceuticals is a clinical-stage oncol...
CTI BioPharma is a biopharmaceutical company focused on the acquisition, developme...
CTI BioPharma is a biopharmaceutical company fo...
Join the National Investor Network and get the latest information with your interests in mind.